DDW: Single Daily Pill Knocks out HCV in Prior Nonresponders
Key clinical point: A fixed dose combination of grazoprevir and elbasvir, with or without ribavirin, was effective in patients with previously treated HCV infections.
Major finding: SVR12 was 92% for patients who received the combination of grazoprevir and elbasvir alone, compared with 94% for patients who received the antivirals plus ribavirin for 12 weeks.
Data source: Randomized clinical trial of 420 patients with HCV genotypes 1, 4, and 6 for whom prior therapy with peg-interferon/ribavirin had failed.
Disclosures: Dr. Kwo disclosed ties with Merck, which supported the C-EDGE study.
AT DDW 2015
The combination has received two Breakthrough Therapy designations from the Food and Drug Administration for patients with HCV genotype 4, and for patients with genotype 1 infections who are on hemodialysis for end stage renal disease. The breakthrough designation makes the drug eligible for expedited review.
Dr. Kwo disclosed ties with Merck, which supported the C-EDGE study.
